Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Invested Capital (2016 - 2025)

Historic Invested Capital for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $654.3 million.

  • Ocular Therapeutix's Invested Capital rose 10749.09% to $654.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $654.3 million, marking a year-over-year increase of 10749.09%. This contributed to the annual value of $654.3 million for FY2025, which is 10749.09% up from last year.
  • As of Q4 2025, Ocular Therapeutix's Invested Capital stood at $654.3 million, which was up 10749.09% from $258.2 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Invested Capital high stood at $654.3 million for Q4 2025, and its period low was $3.1 million during Q2 2023.
  • Moreover, its 5-year median value for Invested Capital was $104.1 million (2021), whereas its average is $188.7 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Invested Capital crashed by 9530.87% in 2023, and later surged by 1213501.78% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Invested Capital (Quarter) stood at $120.9 million in 2021, then tumbled by 39.72% to $72.9 million in 2022, then soared by 76.49% to $128.6 million in 2023, then soared by 145.15% to $315.3 million in 2024, then skyrocketed by 107.49% to $654.3 million in 2025.
  • Its Invested Capital was $654.3 million in Q4 2025, compared to $258.2 million in Q3 2025 and $305.9 million in Q2 2025.